Pfizer Moves To Block Unichem Over Xeljanz Patent
This article was originally published in Scrip
Executive Summary
Pfizer has moved court against Unichem Laboratories seeking to block the Indian firm from allegedly infringing its patents concerning the rheumatoid arthritis therapy, tofacitinib (Xeljanz).